381 related articles for article (PubMed ID: 26239822)
1. Low expression of DLC1 is predictive of poor therapeutic efficiency of fluoropyrimidine and oxaliplatin as adjuvant chemotherapy in gastric cancer.
Su Y; Lin L; Zhang J; Jiang Y; Pan C; Sun L; Duan J; Liao W
Mol Med Rep; 2015 Oct; 12(4):5771-9. PubMed ID: 26239822
[TBL] [Abstract][Full Text] [Related]
2. Expression of GRP78 predicts taxane-based therapeutic resistance and recurrence of human gastric cancer.
Yang L; Yang S; Liu J; Wang X; Ji J; Cao Y; Lu K; Wang J; Gao Y
Exp Mol Pathol; 2014 Apr; 96(2):235-41. PubMed ID: 24602846
[TBL] [Abstract][Full Text] [Related]
3. 15-PGDH expression as a predictive factor response to neoadjuvant chemotherapy in advanced gastric cancer.
Hu M; Li K; Maskey N; Xu Z; Peng C; Tian S; Li Y; Yang G
Int J Clin Exp Pathol; 2015; 8(6):6910-8. PubMed ID: 26261578
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
5. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy.
Qian J; Qian Y; Wang J; Gu B; Pei D; He S; Zhu F; Røe OD; Xu J; Liu L; Gu Y; Guo R; Yin Y; Shu Y; Chen X
Drug Des Devel Ther; 2016; 10():241-58. PubMed ID: 26966350
[TBL] [Abstract][Full Text] [Related]
6. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
7. Pre-adjuvant chemotherapy leukocyte count may predict the outcome for advanced gastric cancer after radical resection.
Pei D; Zhu F; Chen X; Qian J; He S; Qian Y; Shen H; Liu Y; Xu J; Shu Y
Biomed Pharmacother; 2014 Mar; 68(2):213-7. PubMed ID: 24581723
[TBL] [Abstract][Full Text] [Related]
8. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
[TBL] [Abstract][Full Text] [Related]
9. DLC-1 is an independent prognostic marker and potential therapeutic target in hepatocellular cancer.
Song LJ; Liu Q; Meng XR; Li ShL; Wang LX; Fan QX; Xuan XY
Diagn Pathol; 2016 Feb; 11():19. PubMed ID: 26846339
[TBL] [Abstract][Full Text] [Related]
10. [Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
You KY; Peng HH; Gao YH; Chen L; Zhou GQ; Chang H; Du XJ; Xiao L; Zeng ZF; Wen BX; Liu MZ
Zhonghua Zhong Liu Za Zhi; 2013 Sep; 35(9):708-13. PubMed ID: 24332061
[TBL] [Abstract][Full Text] [Related]
11. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
[TBL] [Abstract][Full Text] [Related]
12. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
13. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer.
Jiang N; Deng JY; Ding XW; Ke B; Liu N; Liang H
J Surg Res; 2014 Nov; 192(1):90-7. PubMed ID: 24953988
[TBL] [Abstract][Full Text] [Related]
14. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
[TBL] [Abstract][Full Text] [Related]
15. FPR2 promotes invasion and metastasis of gastric cancer cells and predicts the prognosis of patients.
Hou XL; Ji CD; Tang J; Wang YX; Xiang DF; Li HQ; Liu WW; Wang JX; Yan HZ; Wang Y; Zhang P; Cui YH; Wang JM; Bian XW; Liu W
Sci Rep; 2017 Jun; 7(1):3153. PubMed ID: 28600569
[TBL] [Abstract][Full Text] [Related]
16. Tumor Size Improves the Accuracy of the Prognostic Prediction of Lymph Node-Negative Gastric Cancer.
Liang Y; Liu L; Xie X; Xia L; Meng J; Xu R; He D
J Surg Res; 2019 Aug; 240():89-96. PubMed ID: 30913463
[TBL] [Abstract][Full Text] [Related]
17. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
[TBL] [Abstract][Full Text] [Related]
18. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
[TBL] [Abstract][Full Text] [Related]
19. miR-126: An indicator of poor prognosis and recurrence in histologically lymph node-negative gastric cancer.
Feng R; Sah BK; Li J; Lu S; Yuan F; Jin X; Yan M; Liu B; Li C; Zhu Z
Cancer Biomark; 2018; 23(3):437-445. PubMed ID: 30248047
[TBL] [Abstract][Full Text] [Related]
20. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
